Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • GlaxoSmithKline, Aspen deal

    GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Aspen Pharmacare Holdings Ltd. (JSE:APN), Durban, South Africa Business: Hematology, Pharmaceuticals Aspen exercised an option to acquire GlaxoSmithKlines thrombosis …

    Published on 9/19/2016
  • Imagu Vision Technologies, iCarbonX deal

    Imagu Vision Technologies Ltd., Tel Aviv, Israel iCarbonX, Shenzhen, China Business: Other Artificial intelligence and personalized health company iCarbonX will acquire Imagu Vision Technologies, a computer imaging and …

    Published on 9/19/2016
  • MacroGenics, Takeda deal

    MacroGenics Inc. (NASDAQ:MGNX), Rockville, Md. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Autoimmune Takeda terminated its option agreement and returned rights to bispecific antibody MGD010 to …

    Published on 9/19/2016
  • OncoImmune, Pfizer deal

    OncoImmune Inc., Rockville, Md. Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Cancer, Antibodies OncoImmune granted Pfizer an exclusive option to license rights to ONC-392, a preclinical mAb against cytotoxic T-…

    Published on 9/19/2016
  • Otsuka Pharmaceutical, Senju deal

    Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Senju Pharmaceutical Co. Ltd., Osaka, Japan Business: Ophthalmic Otsuka granted Senju co-promotion rights in Japan for carteolol/latanoprost (OPC-1085EL). Last year, Otsuka …

    Published on 9/19/2016
  • Raptor, Horizon Pharma deal

    Raptor Pharmaceutical Corp. (NASDAQ:RPTP), Novato, Calif. Horizon Pharma plc (NASDAQ:HZNP), Dublin, Ireland Business: Infectious, Renal Horizon will acquire Raptor for $9 per share in a cash deal that the companies say …

    Published on 9/19/2016
  • Regeneron, Neovii Pharmaceuticals deal

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Neovii Pharmaceuticals AG, Rapperswil, Switzerland Business: Inflammation Regeneron granted Neovii worldwide rights, except in the U.S. and Japan, to develop…

    Published on 9/19/2016
  • Sanofi, Verily deal

    Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Verily Life Sciences, Mountain View, Calif. Business: Endocrine/Metabolic Sanofi and Verily launched Onduo (Cambridge, Mass.), a JV that plans to develop a diabetes …

    Published on 9/19/2016
  • Soligenix, SciClone deal

    Soligenix Inc. (OTCBB:SNGX), Princeton, N.J. SciClone Pharmaceuticals Inc. (NASDAQ:SCLN), Foster City, Calif. Business: Other The partners added commercialization and development rights in Taiwan, South Korea and …

    Published on 9/19/2016
  • Takeda, Dermira deal

    Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Dermira Inc. (NASDAQ:DERM), Menlo Park, Calif. Business: Dermatology Takeda granted Dermira an option to license exclusive, worldwide rights to develop and …

    Published on 9/19/2016
  • Vitae, Allergan deal

    Vitae Pharmaceuticals Inc. (NASDAQ:VTAE), Fort Washington, Pa. Allergan plc (NYSE:AGN), Dublin, Ireland Business: Autoimmune Allergan will acquire Vitae for $21 per share in cash in a deal the companies say values Vitae…

    Published on 9/19/2016
  • Voyager Therapeutics, CHDI Foundation deal

    Voyager Therapeutics Inc. (NASDAQ:VYGR), Cambridge, Mass. CHDI Foundation Inc., New York, N.Y. Business: Neurology Voyager and CHDI partnered to advance Voyagers VY-HTT01 into clinical trials to treat Huntingtons …

    Published on 9/19/2016
  • Arena, Beacon Discovery deal

    Arena Pharmaceuticals Inc. (NASDAQ:ARNA), San Diego, Calif. Beacon Discovery Inc., San Diego, Calif. Business: Pharmaceuticals Arena formed newco Beacon Discovery to discover and develop molecules targeting GPCRs. Arena…

    Published on 9/12/2016
  • Aurigene, Curis deal

    Aurigene Discovery Technologies Ltd., Bangalore, India Curis Inc. (NASDAQ:CRIS), Lexington, Mass. Business: Cancer The partners amended a 2015 deal granting Curis options to license exclusive, worldwide rights outside …

    Published on 9/12/2016
  • BioLineRx, Genentech, Roche deal

    BioLineRx Ltd. (Tel Aviv:BLRX;NASDAQ:BLRX), Jerusalem, Israel Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Cancer BioLineRx and Roches Genentech unit partnered to…

    Published on 9/12/2016
  • Cepheid, Danaher deal

    Cepheid Inc. (NASDAQ:CPHD), Sunnyvale, Calif. Danaher Corp. (NYSE:DHR), Washington, D.C. Business: Diagnostic Lab equipment and diagnostics company Danaher is acquiring molecular diagnostic play Cepheid for $53 per …

    Published on 9/12/2016
  • Fate Therapeutics, Memorial Sloan Kettering deal

    Fate Therapeutics Inc. (NASDAQ:FATE), San Diego, Calif. Memorial Sloan Kettering Cancer Center, New York, N.Y. Business: Gene/Cell therapy Fate Therapeutics partnered with Memorial Sloan Kettering Cancer Center (MSKCC) …

    Published on 9/12/2016
  • Fujifilm deal

    Fujifilm Holdings Corp. (Tokyo:4901), Tokyo, Japan Business: Gene/Cell therapy Fujifilms Cellular Dynamics International Inc. company will divide its operations into therapeutics and life science business units. The …

    Published on 9/12/2016
  • Horizon Discovery, Fulcrum Therapeutics deal

    Horizon Discovery Group plc (LSE:HZD), Cambridge, U.K. Fulcrum Therapeutics Inc., Cambridge, Mass. Business: Gene/Cell therapy Horizon partnered with Fulcrum to use Horizons CRISPR-based screening platform to identify …

    Published on 9/12/2016
  • Merck, Aralez deal

    Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ;TSX:ARZ), Milton, Ontario Business: Cardiovascular Aralez purchased U.S. and Canadian rights to Zontivity vorapaxar from Merck. The …

    Published on 9/12/2016
  • PeptiDream, Tokyo Institute of Technology deal

    PeptiDream Inc. (Tokyo:4587), Tokyo, Japan Tokyo Institute of Technology, Tokyo, Japan Business: Pharmaceuticals, Computational chemistry/biology PeptiDream and the institute partnered to discover and develop in silico …

    Published on 9/12/2016
  • RetroSense Therapeutics, Allergan deal

    RetroSense Therapeutics LLC, Ann Arbor, Mich. Allergan plc (NYSE:AGN), Dublin, Ireland Business: Ophthalmic Allergan acquired RetroSense for $60 million in cash up front and undisclosed regulatory and commercialization …

    Published on 9/12/2016
  • twoXAR, Stanford University deal

    twoXAR Inc., Palo Alto, Calif. Stanford University, Stanford, Calif. Business: Cancer, Computational chemistry/biology Computational drug discovery firm twoXAR partnered with Stanford University School of Medicines …

    Published on 9/12/2016
  • UCSD, RetroSense Therapeutics deal

    University of California San Diego, La Jolla, Calif. RetroSense Therapeutics LLC, Ann Arbor, Mich. Business: Ophthalmic The university granted RetroSense exclusive, worldwide rights to develop red activatable …

    Published on 9/12/2016
  • Agency for Science, Technology and Research, Aslan deal

    Agency for Science, Technology and Research, Singapore Aslan Pharmaceuticals Pte. Ltd., Singapore Business: Cancer The Agency for Science, Technology and Research (A*STAR) granted Aslan worldwide rights to a preclinical…

    Published on 9/5/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993